Atorvastatin in the TREATment of Intracranial Unruptured VertebroBasilar Dissecting Aneurysms

• Status: Not yet recruiting
• Trial end date: 2022-07-30
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to whether there is a measurable reduction in inflammation in walls of unruptured vertebrobasilar dissecting aneurysms with atorvastatin.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Neurosurgical Institute
• Treatments: Atorvastatin

Criteria

Inclusion Criteria:

1. Be aged 18 or over, male or non-pregnant female;

2. Patients have a unruptured vertebrobasilar dissecting aneurysm identified on imaging (CT, MRI or DSA)

3. Patients with wall enhancement and intramural hematomas of UVBDAs by HR-VW-MRI before treatment.

4. Patients who is able to understand the objective of the trail, agrees and signs the written informed consent form.

Exclusion Criteria:

1. The aneurysm types of non-dissecting aneurysm, such as saccular aneurysms, fusiform aneurysms and traumatic aneurysms, etc.;

2. Patients with MRI contraindications: metallic implant, contrast allergy, claustrophobia, etc.;

3. Planned treatment of the aneurysm within 6 months;

4. Several impaired liver or renal functions;

5. Retreatment of recurrent aneurysm;

6. Pregnant or lactating women;

7. Patients with malignant diseases, such as liver disease, kidney diseases, congestive heart failure, malignant tumors, etc.;

8. Poor compliance patients;